SeaStar Medical plans to progress programmes for acute and chronic inflammations. Credit: JAFAR AHMED / Unsplash.

SeaStar Medical and LMF Acquisition Opportunities (LMAO), a company sponsored by LM Funding America, have announced the completion of a merger agreement.

Announced in April, the deal is anticipated to create nearly $85m enterprise value For SeaStar Medical.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Following unanimous approval by the boards of both companies, LMAO has been rebranded SeaStar Medical Holding Corporation.

The combined entity will become a publicly listed company, with its common stock and warrants set to commence trading on Nasdaq soon.

SeaStar Medical Holding Corporation president and CEO Eric Schlorff said: “This transaction provides us greater resources to advance our Selective Cytopheretic Device (SCD) for patients suffering from the devastating consequences of hyperinflammation.

“We have submitted our Humanitarian Device Exemption (HDE) application to the US Food and Drug Administration (FDA) for paediatric use, and we plan to launch a pivotal study of the SCD in adults with acute kidney injury (AKI) in the first quarter of 2023.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“As a public company, we will be better positioned to move these programmes forward.”

Through this deal, SeaStar Medical plans to progress other programmes for acute and chronic inflammations, including Covid-19-associated conditions.

Under the terms of the merger, the new company will be run by the management team of SeaStar Medical, led by Schlorff.

Caryl Baron will be the company’s interim CFO.

LM Funding chairman and CEO Bruce Rodgers said: “We are extremely pleased that the transaction received the overwhelming support of the stockholders of LMF Acquisition and believe it will unlock significant value for the stockholders of LM Funding and SeaStar Medical.

“We look forward to supporting SeaStar Medical Holding Corporation as they continue to advance potentially lifesaving therapies as a public company.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact